Company Profile
Supernus Stock Price, News & Catalysts
- Ticker:
- SUPN
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
45.85 USD (-3.37%)
Close
Last updated: August 21, 2026
2.56B USD
Market cap
Why the stock is moving
As of Aug 21, 2026, SUPN closed down 3.37% at $45.85. No new same-company headline was identified in the current news window.
Company overview
CNS Commercial Portfolio
Supernus Pharmaceuticals develops and commercializes treatments for central nervous system disorders. Its marketed portfolio spans attention-deficit hyperactivity disorder, Parkinson’s disease, postpartum depression, epilepsy, migraine, cervical dystonia and chronic sialorrhea.
Growth Products
The company’s principal growth brands include Qelbree for ADHD, GOCOVRI for dyskinesia in Parkinson’s disease, ONAPGO for continuous treatment of motor fluctuations in Parkinson’s disease and ZURZUVAE for postpartum depression. ZURZUVAE is commercialized through an economic collaboration with Biogen.
Epilepsy and Depression Pipeline
SPN-817 is a selective acetylcholinesterase inhibitor in a Phase 2b trial for treatment-resistant focal seizures. SPN-820 is designed to increase mTORC1-mediated synaptic function and is in Phase 2b development as an adjunctive treatment for major depressive disorder.
ADHD Pipeline Expansion
SPN-443 is a novel stimulant candidate for ADHD. Its planned first-in-human study extends Supernus’s pipeline within a therapeutic area where the company already has commercial infrastructure through Qelbree.
Future catalysts
- Phase 1 initiation for SPN-443 expected in the second half of 2026.
- FDA submission for a second ONAPGO supplier expected in the third quarter of 2026, with potential approval by mid-2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Supernus (SUPN)?
Supernus (SUPN) most recently closed at 45.85 USD, a -3.37% move versus the previous session.
What is the market cap of Supernus (SUPN)?
Supernus currently has a market capitalization of 2.56B USD on BioPharmSignal.
What does Supernus do?
CNS Commercial Portfolio Supernus Pharmaceuticals develops and commercializes treatments for central nervous system disorders. Its marketed portfolio spans attention-deficit hyperactivity disorder, Parkinson’s disease, postpartum depression, epilepsy, migraine, cervical dystonia and chronic sialorrhea. Growth Products The company’s principal growth brands...
On which exchange is SUPN stock listed?
Supernus (SUPN) is associated with NASDAQ, United States, Biopharma.
What is SPN-817?
Epilepsy and Depression Pipeline SPN-817 is a selective acetylcholinesterase inhibitor in a Phase 2b trial for treatment-resistant focal seizures.
Which conditions is Supernus targeting with SPN-817?
CNS Commercial Portfolio Supernus Pharmaceuticals develops and commercializes treatments for central nervous system disorders. Its marketed portfolio spans attention-deficit hyperactivity disorder, Parkinson’s disease, postpartum depression, epilepsy, migraine, cervical dystonia and chronic sialorrhea. Growth Products The company’s principal growth brands...
How does Supernus describe recent progress with SPN-817?
Phase 1 initiation for SPN-443 expected in the second half of 2026. FDA submission for a second ONAPGO supplier expected in the third quarter of 2026, with potential approval by mid-2027.
What is SPN-820?
SPN-820 is designed to increase mTORC1-mediated synaptic function and is in Phase 2b development as an adjunctive treatment for major depressive disorder.